PayerTalkCE Presents: The Rapidly Evolving Atopic Dermatitis Treatment Paradigm

Expert Faculty Author:

Adam Friedman, MD
Professor and Chair of Dermatology
Director of Translational Research
The George Washington University School of Medicine and Health Sciences
Click here for biography

Steven Kheloussi, PharmD, MBA
Adjunct Professor of Pharmacy Practice
Wilkes University
Click here for biography

Target Audience
This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
An action plan to enhance knowledge of clinical, economic, and humanistic burden of AD is needed by managed care and payer decision makers to enact health care benefit policy strategies to reduce the disease burden and enhance the potential for optimal treatment outcomes. These health care professionals also need increased knowledge of recently approved and emerging AD therapies in order to develop and implement AD benefit design strategies that support an improvement in overall patient quality of life and clinical outcomes. This includes knowledge of the heterogeneity of the presentation of AD and the need to align specific therapies with specific patient types. Furthermore, it is clear that payers can benefit from dermatology providers’ experience and expertise when creating PA criteria in order to streamline utilization controls in order to improve patient access to appropriate therapy.

Educational Objectives
After completing this activity, the participant should be better able to:

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER), the National Eczema Association and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional continuing Education (IPCE) credit for learning and change

Physician Continuing Medical Education
Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 0.5 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA0003680-9999-22-034-H01-P
This activity is certified as Knowledge-based CPE

Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
Medical Education Resources designates this enduring activity for a maximum of 0.5 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

Disclosure of Relevant Financial Relationships
Medical Education Resources insures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Name of Working Group Members/Planners

Reported Financial Relationship

Adam Friedman, MD Consulting fees (e.g. advisory boards): Sanova Works, Amgen, La Roche-Posay Laboratorie Pharmaceutique, Galderma USA, Pfizer, Biogen, Valeant Pharmaceuticals North America LLC, Intraderm Pharmaceuticals, Oculus Innovative Science, Inc., Novartis, Johnson and Johnson Consumer Products Company, Encore Dermatology, Inc., Exeltis, Promius Pharma, LLC., Eli Lilly and Company, Derrmira, Menlo Therapeutics, Ortho Dermatologics, Hoth Therapeutics, Greenway Therapeutix, Brickell Biotech, Inc.
Steven Kheloussi, PharmD, MBA No financial interest/relationships relating to the topic of this activity.

The MER planners and managers have nothing to disclose.
The NEA planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

There is no fee for this educational activity.